AVXL.US Anavex Life Sciences Corp

Healthcare Biotechnology USA Stocks
0.9335 USD
Close of Nov 13, 2026
0.9165 5.36
Market cap
USD 86.5M
P/E
-
P/B
0.81x
ROE
-3.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is AVXL.US undervalued?

Graham number

The Graham number of Anavex Life Sciences Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Anavex Life Sciences Corp fundamental analysis

No fundamental analysis for Anavex Life Sciences Corp yet.

Anavex Life Sciences Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Anavex Life Sciences Corp

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's dis…

Full company profile